Pierre A. Morgon
CEO of MRGN Advisors and Regional Partner for Switzerland
Pierre A. MORGON is Chief Executive Officer of MRGN Advisors and Regional Partner for Switzerland at Mérieux Développement, an evergreen investment structure focused on medical devices, in vitro diagnostics and patient management services.
He is also Chairman of the Board of Virometix, a Swiss company developing proprietary synthetic nanoparticle platform in vaccines and immunotherapeutic drugs for viral diseases and cancer, as well as Non-Executive Director to the Board of Theradiag, a French company focusing on in vitro diagnostics in auto-immunity, infectious diseases and allergy, and Non-Executive Director to the Board of Eurocine Vaccines, a Swedish company dedicated to developing nasal vaccines.
Pierre has over 30 years of experience in the global life science industry and in healthcare information technology, both at the helm of large and diversified teams in business operations and in C-level positions at global level. He is a lecturer in several MBA programs in world-class business schools and is frequently invited to deliver keynote presentations in life science conferences.
He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD, IMD and MCE executive programs.